Similarly, the Kaplan-Meier survival analysis showed that pyrimidine metabolic rate–limiting enzymes DTYMK, NT5C3, RRM1, RRM2, TK1, TYMS, and UCK2 were all associated with adverse prognosis in the lung cancer (Fig. 6a). Here, TYMS is linked to lung cancer.